Dravet syndrome care technology platforms are the digital infrastructure underpinning modern management of one of the most severe and pharmacologically challenging epilepsies of early childhood — a catastrophic epileptic encephalopathy defined by loss-of-function mutations in the SCN1A gene encoding the voltage-gated sodium channel alpha-1 subunit Nav1.1, with the vast majority of cases arising de novo (new mutations not inherited from either parent, occurring in the germline or early embryogenesis) in an otherwise neurologically normal infant who typically presents between 5 and 12 months of age with the first febrile-triggered prolonged generalized tonic-clonic or hemiclonic seizure that inaugurates a lifetime of treatment-resistant epilepsy, neurodevelopmental regression, and complex multisystem management, characterized clinically by fever-triggered seizures that are pathognomonic for the syndrome in its initial phase (febrile seizures with extreme duration, often exceeding 30 minutes, constituting true febrile status epilepticus in many affected infants at first presentation), the subsequent emergence of afebrile seizures of multiple types including myoclonic, atypical absence, focal, and generalized tonic-clonic seizures that develop over the first two years of life, the progressive neurodevelopmental regression with intellectual disability, language delay, autism spectrum features, gait abnormality with ataxia and crouched posture, and behavioral dysregulation that characterizes the encephalopathic course of Dravet syndrome across childhood and into adult life, the thermosensitivity that makes elevated body temperature — whether from fever, hot baths, exercise, or warm environments — the principal seizure trigger that families and clinicians must continuously anticipate and mitigate, and the SUDEP (sudden unexpected death in epilepsy) risk that is among the highest in any epilepsy syndrome, with epidemiological studies documenting mortality rates substantially exceeding the general epilepsy population — integrated across molecular genetic diagnosis platforms that confirm SCN1A pathogenic variant identity and classify variant type (missense, truncating, splice-site, large deletion) for prognostic staging and genetic counseling, seizure surveillance and thermosensitivity monitoring platforms tracking fever onset, ambient temperature, and seizure occurrence relationships for trigger anticipation and emergency protocol activation, sodium channel blocker contraindication management platforms that flag the multiple antiseizure medications — carbamazepine, oxcarbazepine, lamotrigine, phenytoin, and others — that paradoxically worsen Dravet syndrome seizures through Nav1.1 blockade that reduces the inhibitory interneuron activity that Nav1.1 normally supports, precision treatment management platforms for fenfluramine, cannabidiol (Epidiolex), and stiripentol — the three FDA/EMA-approved Dravet-specific therapies — alongside valproate, clopazam, and topiramate in standard combination regimens, emergency protocol platforms managing the buccal midazolam, intranasal diazepam, intranasal midazolam, and rectal diazepam rescue medication protocols that families and school nurses require for prolonged seizure management given the extreme seizure duration propensity that defines Dravet syndrome, and multidisciplinary Dravet syndrome clinic coordination infrastructure integrating pediatric epileptologists, neuropsychologists, developmental pediatricians, genetic counselors, school accommodation specialists, physical and occupational therapists, speech-language pathologists, and palliative care specialists who collectively manage a condition where the epilepsy, neurodevelopmental sequelae, sodium channel blocker contraindications, thermosensitivity, SUDEP risk, and caregiver burden require continuous coordinated digital surveillance across every clinical domain simultaneously. When a Dravet syndrome care platform is unavailable or degraded, multidisciplinary teams cannot access the seizure frequency trends, rescue medication administration histories, fenfluramine cardiac surveillance records, SCN1A variant classification, sodium channel blocker contraindication alerts, thermosensitivity trigger logs, emergency protocol activation histories, and neurodevelopmental trajectory data that guide management of a syndrome where missed contraindication alerts, delayed rescue protocols, and unmonitored cardiac surveillance represent preventable harm.
This guide covers what Dravet syndrome care technology platforms need to monitor, why continuous availability matters across the full clinical spectrum including seizure surveillance, thermosensitivity management, sodium channel blocker contraindication enforcement, precision therapy monitoring, emergency rescue protocol coordination, and neurodevelopmental surveillance, and how to build a monitoring strategy that protects the complex multi-domain clinical monitoring that Dravet syndrome care requires.
Why Dravet Syndrome Care Tech Platforms Cannot Afford Downtime
Dravet syndrome management is built on five pillars: precision antiseizure pharmacology requiring absolute contraindication enforcement for sodium channel blockers (carbamazepine, oxcarbazepine, lamotrigine, phenytoin, rufinamide, and vigabatrin in certain protocols) that universally worsen seizure control in Dravet syndrome by further suppressing Nav1.1-mediated inhibitory interneuron activity — contraindication alerts that must be visible to every prescribing provider across every care setting including emergency departments, inpatient units, and on-call providers who may encounter Dravet patients without immediate access to specialist documentation and who may inadvertently prescribe contraindicated agents that precipitate catastrophic status epilepticus; thermosensitivity monitoring and emergency protocol activation integrating real-time temperature surveillance, fever detection alerts, rescue medication readiness verification, and emergency protocol communication to families, school nurses, and emergency responders managing a condition where a 1-degree Celsius temperature rise can trigger prolonged status epilepticus requiring immediate rescue intervention and where the interval between fever onset and rescue medication administration is the critical safety window; Dravet-specific precision therapy management providing the fenfluramine cardiac surveillance scheduling (mandatory echocardiography and cardiac valve monitoring given fenfluramine's historical association with valvular heart disease at higher doses in adults and its required cardiac monitoring program at approved pediatric doses), cannabidiol pharmacokinetic monitoring for hepatotoxicity risk stratification particularly in patients on concurrent valproate where the drug-drug interaction substantially elevates hepatic enzyme elevation risk, stiripentol drug interaction management for its CYP450 enzyme inhibition effects that require dose adjustments in concurrent antiseizure medications, and combination pharmacotherapy optimization in the multi-agent regimens that most Dravet patients require; emergency rescue medication protocol management providing the family education, school and daycare nurse training, community first responder pre-notification, and emergency department awareness infrastructure that ensures families can administer buccal midazolam or intranasal diazepam within the first minutes of prolonged seizures and that emergency responders know to avoid sodium channel blockers in prehospital management; and SUDEP risk monitoring and mitigation providing the nocturnal seizure surveillance, sleep-safe positioning guidance, SUDEP risk communication to families, seizure alarm coordination, and the continuous monitoring awareness that SUDEP risk in Dravet syndrome exceeds that of virtually any other epilepsy syndrome — requiring continuous platform availability for the seizure diary, rescue protocol, cardiac surveillance, and emergency protocol coordination that constitutes the SUDEP risk mitigation infrastructure. The platforms that support Dravet syndrome programs must remain continuously available — because an unmonitored Dravet patient whose sodium channel blocker contraindication alerts are inaccessible to an emergency department provider, whose fenfluramine cardiac surveillance is overdue without platform detection, whose rescue medication training records are unavailable to a new school nurse, whose thermosensitivity monitoring has lapsed during fever season, or whose SUDEP risk communication has not been updated when seizure frequency escalates represents a preventable harm cascade that timely digital surveillance could have intercepted.
Sodium channel blocker contraindication enforcement is the most time-critical patient safety domain in Dravet syndrome care. SCN1A loss-of-function pathology means Nav1.1 channels are already haploinsufficient, and additional sodium channel blockade further reduces the inhibitory interneuron excitability on which seizure inhibition depends — creating a paradoxical worsening where sodium channel blockers that are standard antiseizure therapy in most epilepsies reliably precipitate seizure exacerbation, status epilepticus, and acute deterioration in Dravet syndrome. Emergency department providers, hospitalist physicians, on-call neurologists, and anesthesiologists encountering Dravet patients may not immediately recognize the sodium channel blocker contraindication, and a platform that cannot deliver contraindication alerts when a prescribing provider accesses a Dravet patient's record creates a prescribing safety window that is directly preventable through continuous platform availability and alert delivery. Platform failures that disable contraindication alert systems for Dravet patients accessing care in non-specialist settings represent the highest-risk monitoring failure in Dravet syndrome management.
Fenfluramine cardiac surveillance is the most distinctive pharmacovigilance obligation in Dravet syndrome. Fenfluramine received FDA approval for Dravet syndrome seizure reduction in 2020 under a restricted REMS program requiring echocardiographic monitoring of cardiac valves and pulmonary arterial pressure at specified intervals — baseline prior to initiation, then every 6 months — given the known association between serotonin pathway stimulation and cardiac valvulopathy at the doses used historically in adult obesity treatment. The echocardiographic surveillance program must be maintained continuously across the treatment course; platform failures that prevent surveillance scheduling, overdue alert generation, and cardiology liaison coordination create gaps in fenfluramine cardiac monitoring that the REMS program specifically exists to prevent. Pediatric epileptologists and cardiologists coordinating fenfluramine REMS compliance require continuous platform availability for echocardiography scheduling, result integration, and overdue surveillance alert generation.
Thermosensitivity monitoring is a distinctive continuous surveillance obligation without parallel in most other epilepsy syndromes. The extreme thermosensitivity that defines Dravet syndrome requires continuous ambient temperature and fever surveillance with immediate escalation to rescue protocol activation — not because fever is itself preventable (it is not) but because the interval between fever onset, rescue medication administration, and emergency response activation is the determinant of whether a prolonged febrile seizure progresses to refractory status epilepticus, respiratory compromise, or hospitalization. Platforms that track daily temperature readings, log fever events, document rescue medication administration timestamps, and maintain school and home emergency protocol compliance cannot be allowed to lapse without activating manual surveillance alternatives for a condition where thermosensitivity management is continuous and temperature surveillance is a 24/7 obligation across every environment the child occupies.
What to Monitor on a Dravet Syndrome Care Tech Platform
Sodium Channel Blocker Contraindication Alert Platform
The sodium channel blocker contraindication alert service — integrating SCN1A-positive Dravet diagnosis flags with prescribing decision support that generates real-time contraindication alerts when carbamazepine, oxcarbazepine, lamotrigine, phenytoin, fosphenytoin, rufinamide, lacosamide, and other sodium channel-blocking antiseizure medications are prescribed or administered, emergency department integration ensuring that Dravet contraindications are surfaced to emergency providers encountering patients without specialist documentation, inpatient pharmacy integration for automatic contraindication review on admission medication reconciliation, anesthesia pre-procedure screening with Dravet-specific anesthetic consideration alerts, cross-facility contraindication record sharing for patients receiving care across multiple health systems, escalation alert generation for contraindicated medication prescriptions requiring immediate specialist review, and audit logging of contraindication alert overrides requiring pharmacist and specialist cosignature — is the highest-priority monitoring target. Check at a 1-minute interval with immediate escalation. Sodium channel blocker contraindication alert platform failures represent the single most dangerous monitoring failure in Dravet syndrome management because they create an undetected prescribing safety window during every emergency or non-specialist care encounter.
Fenfluramine REMS Cardiac Surveillance Platform
Monitor the fenfluramine REMS cardiac surveillance management service — including echocardiographic surveillance scheduling at baseline and every 6-month intervals per REMS program requirements, echocardiography result receipt and cardiac valve and pulmonary pressure grading integration, overdue surveillance alert generation with escalating urgency for patients approaching or exceeding REMS-specified interval limits, cardiology liaison coordination for surveillance abnormality follow-up, fenfluramine dose modification decision support based on cardiac surveillance results, REMS enrollment verification and compliance documentation, prescribing authorization management for REMS-certified prescribers, pharmacy dispensing authorization integration, patient and family education documentation on cardiac symptom surveillance, and REMS non-compliance escalation alert generation for patients overdue for required echocardiographic surveillance — at a 1-minute interval. Fenfluramine REMS cardiac surveillance is a regulatory and safety obligation that cannot be maintained through manual processes during platform outages; patients receiving fenfluramine without current echocardiographic surveillance are non-compliant with the REMS program that exists to detect drug-induced cardiac valvulopathy before it causes irreversible cardiac injury.
Thermosensitivity and Fever Monitoring Platform
Monitor the thermosensitivity surveillance and fever monitoring service — including continuous ambient temperature logging for home environments with alerting at threshold temperatures that approach seizure risk ranges, fever onset detection through connected thermometry with immediate family notification and rescue medication readiness verification, fever management protocol activation tracking with acetaminophen and ibuprofen administration logging and alert generation for escalating fever not responding to antipyretics, school and daycare temperature monitoring integration with nurse notification for fever or elevated ambient temperature during the school day, exercise and physical activity temperature management protocol coordination, hot bath and warm swimming alert protocols for summer heat exposure management, thermosensitivity diary integration with seizure occurrence correlation analysis, urgent notification generation for temperature events in children whose seizure threshold history indicates particular thermosensitivity, and seasonal thermosensitivity management protocol updates for summer heat waves, illness season, and exercise-related temperature exposure — at a 1-minute interval. Thermosensitivity monitoring failures in Dravet syndrome create undetected fever exposure windows during which seizure risk is maximally elevated without rescue protocol readiness confirmation.
Seizure Diary and Rescue Medication Protocol Platform
Monitor the seizure diary and rescue medication coordination service — including family-facing seizure diary with type classification, duration, cluster pattern, and rescue medication administration logging, seizure frequency trend analysis with escalation alert generation for frequency increases from individual baseline, rescue medication administration timestamp logging with response time analysis, rescue medication efficacy documentation with response and additional dose requirement tracking, rescue medication supply management with refill alert generation for families approaching supply depletion, school and daycare nurse training documentation with recertification scheduling and competency renewal alerts, emergency responder pre-notification management with Dravet-specific protocol cards for local EMS and emergency departments, prolonged seizure (>5 minutes) automatic escalation alert generation, rescue medication protocol failure alert for seizures not responding to first-line rescue requiring 911 activation, and cluster seizure pattern alert generation for seizures meeting emergency department evaluation thresholds — at a 1-minute interval. Seizure diary and rescue medication platform availability is the continuous safety monitoring infrastructure for a syndrome where seizures frequently exceed 30 minutes and where the timely administration of rescue medication within the first 5 minutes is the primary determinant of status epilepticus prevention.
Precision Therapy Management Platform
Monitor the precision antiseizure therapy management service — including fenfluramine dose optimization with seizure reduction tracking against pre-treatment baseline, cannabidiol (Epidiolex) dosing management with liver function test scheduling for hepatotoxicity surveillance — with enhanced monitoring frequency when concurrent valproate creates drug-drug interaction risk for elevated hepatic enzyme elevation, stiripentol drug interaction management with dose adjustment recommendations for concurrent clobazam and valproate whose plasma levels stiripentol's CYP3A4 and CYP2C19 inhibition substantially elevates, valproate therapeutic drug monitoring with dosing optimization and ammonia level surveillance for hyperammonemia, clobazam active metabolite monitoring, topiramate monitoring with metabolic acidosis surveillance, ketogenic diet metabolic surveillance integration for patients using dietary therapy as adjunctive treatment, polypharmacy interaction alert generation across the multi-agent regimens most Dravet patients require, and treatment response trajectory modeling against published Dravet syndrome seizure reduction benchmarks — at a 1-minute interval.
Cannabidiol Hepatotoxicity Surveillance Platform
Monitor the cannabidiol hepatotoxicity surveillance service — including liver function test scheduling at baseline, 1 month, 3 months, and 6 months after initiation then every 6 months during maintenance, transaminase elevation alert generation at the threshold levels specified in Epidiolex prescribing information, dose modification decision support for transaminase elevations requiring dose reduction or discontinuation, valproate interaction risk stratification with enhanced surveillance frequency for patients on concurrent valproate, hepatotoxicity symptom diary integration with family-reported anorexia, vomiting, jaundice, or abdominal pain logging, laboratory result integration from reference laboratory systems, and urgent hepatotoxicity escalation alert generation for severe transaminase elevations requiring immediate nephrology consultation — at a 1-minute interval.
Neurodevelopmental Surveillance Platform
Monitor the neurodevelopmental trajectory surveillance service — including serial cognitive assessment tracking with standardized neurodevelopmental battery scheduling at 6-month intervals, language development milestone surveillance with speech-language pathology referral alert generation for language plateau or regression, autism spectrum features surveillance with behavioral assessment scheduling, motor function and gait assessment coordination with physical therapy referral tracking, adaptive behavior scale serial administration for functional independence trajectory monitoring, school accommodation documentation management with individualized education program coordination, neuropsychological assessment scheduling for school age cognitive profiling, behavior and attention management documentation with behavioral pediatric liaison coordination, and neurodevelopmental regression alert generation requiring urgent epileptology reassessment — at a 1-minute interval. Neurodevelopmental surveillance in Dravet syndrome must capture the progressive cognitive and behavioral trajectory that characterizes the encephalopathic course and must detect regression that may signal subtherapeutic seizure control or unrecognized subclinical seizure activity.
SUDEP Risk Monitoring and Mitigation Platform
Monitor the SUDEP risk surveillance and mitigation service — including nocturnal seizure detection device integration with bed sensor and wearable EEG or accelerometer data logging, SUDEP risk stratification based on seizure frequency, nocturnal seizure occurrence, and clinical risk factor profiling, seizure alarm system compliance monitoring for family adherence to recommended nocturnal surveillance, sleep-safe positioning protocol documentation and family education compliance tracking, SUDEP risk communication documentation confirming that families have received age-appropriate SUDEP risk counseling, emergency response plan review and update scheduling, SUDEP risk escalation alert generation for patients with escalating seizure frequency or increasing nocturnal seizure burden, and bereavement support resource coordination for families experiencing SUDEP events in the Dravet community — at a 2-minute interval. SUDEP risk in Dravet syndrome is among the highest in pediatric epilepsy, with annual mortality rates in the range of 0.5–1% in published cohorts — making continuous SUDEP risk surveillance and nocturnal monitoring compliance a clinical obligation that platform availability directly enables.
Genetic Counseling and SCN1A Registry Platform
Monitor the genetic counseling and SCN1A molecular registry service — including SCN1A pathogenic variant classification with variant type documentation (missense versus truncating versus splice-site versus large deletion, as variant class correlates with phenotypic severity), de novo mutation confirmation with parental testing documentation, recurrence risk counseling documentation for parents of children with de novo SCN1A mutations (approximately 1% empirical recurrence risk from germline mosaicism), genetic counseling coordination for family members of familial SCN1A cases, reproductive genetic counseling for parents considering subsequent pregnancies including preimplantation genetic testing coordination, emerging SCN1A genotype-phenotype correlation documentation for precision phenotyping, clinical trial enrollment eligibility screening based on genetic and phenotypic criteria, and genetic counseling escalation alert generation for newly identified SCN1A variants requiring variant reclassification review — at a 2-minute interval.
Multidisciplinary Clinic Coordination and Telemedicine Platform
Monitor the multidisciplinary Dravet syndrome clinic coordination service — including pediatric epileptologist, developmental pediatrician, neuropsychologist, genetic counselor, physical and occupational therapist, speech-language pathologist, school liaison, social worker, and palliative care specialist scheduling and coordination, telemedicine session management for families in geographically remote locations where Dravet syndrome clinic access requires travel burden that platform-facilitated telehealth can substantially reduce, school and daycare liaison coordination for individualized education plan and 504 accommodation planning, emergency department pre-registration with Dravet-specific management protocols including sodium channel blocker contraindication documentation, and family support group coordination — at a 2-minute interval.
EHR Synchronization Endpoint
Monitor the EHR synchronization service at a 5-minute interval. Dravet syndrome patients presenting to emergency departments or urgent care facilities require immediate provider access to their SCN1A diagnosis, sodium channel blocker contraindication list, current antiseizure medication regimen, rescue medication protocol, fenfluramine REMS status, last echocardiography result, and seizure action plan — with the sodium channel blocker contraindication being the single most critical piece of information that any prescribing provider must have immediately.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock pediatric epileptologists, nurses, pharmacists, and families out of contraindication alert systems, fenfluramine REMS tracking, thermosensitivity monitoring, rescue medication protocols, and seizure diary platforms simultaneously.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, family-facing, and integration domains. Certificate failures block family portal access to rescue medication protocols, thermosensitivity guidance, and the contraindication alert systems that emergency care settings require.
Alerting Strategy for Dravet Syndrome Care Tech Platforms
Immediate clinical escalation (24/7): Sodium channel blocker contraindication alert platform, fenfluramine REMS cardiac surveillance platform, thermosensitivity and fever monitoring platform, seizure diary and rescue medication protocol platform, precision therapy management platform, cannabidiol hepatotoxicity surveillance platform, neurodevelopmental surveillance platform, authentication service. These affect real-time safety monitoring across the most critical Dravet syndrome clinical domains.
Immediate clinical operations escalation: SUDEP risk monitoring and mitigation platform. Access failures interrupt the nocturnal seizure surveillance and SUDEP risk mitigation documentation that constitutes continuous mortality risk management.
High-priority immediate escalation: Genetic counseling and SCN1A registry platform. Access failures interrupt the variant classification and recurrence risk counseling that genetic diagnosis requires.
High-priority immediate escalation: Multidisciplinary clinic coordination and telemedicine platform. Access failures interrupt the specialist coordination across epileptology, developmental pediatrics, and school liaison that Dravet syndrome management requires.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour — with highest priority for failures affecting sodium channel blocker contraindication accessibility in emergency settings.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
Thermosensitivity monitoring and contraindication alert systems require 24/7 alerting because fever events — and the emergency encounters they trigger — occur at any hour and require immediate rescue protocol activation and contraindication-safe emergency management regardless of time.
Status Page as a Clinical Safety Signal
Dravet syndrome families managing after-hours fever events, prolonged seizures, or emergency department visits need immediate platform status awareness before initiating escalation protocols. A published status page allows families and on-call epileptologists to distinguish a platform incident from connectivity problems — and to activate manual monitoring protocols, printed rescue medication plans, phone-based thermosensitivity guidance, and emergency department advance notification when the digital platform is confirmed unavailable.
For Dravet syndrome programs coordinating management across contraindication safety, thermosensitivity surveillance, cardiac monitoring, rescue protocols, and neurodevelopmental tracking, a status page enables rapid identification of platform failures and activation of manual protocols. Publish the status page URL in family emergency kits, school nurse stations, on-call epileptology contact systems, and emergency department Dravet protocol cards.
The Business Case: Treatment Safety, Contraindication Prevention, and SUDEP Risk Reduction
Dravet syndrome specialty programs face significant exposure from sodium channel blocker administration in patients presenting to non-specialist care settings without accessible contraindication documentation — the single most preventable acute harm in Dravet syndrome management; fenfluramine cardiac surveillance gaps from REMS non-compliance that delay valvulopathy detection until clinically significant cardiac injury has occurred; rescue medication protocol failures from untrained school nurses or outdated emergency plans that result in prolonged seizure duration and status epilepticus; thermosensitivity monitoring failures that miss fever onset during unmonitored periods and delay rescue medication administration; hepatotoxicity from cannabidiol-valproate interactions detected late because liver function surveillance platforms were unavailable; and SUDEP events in patients whose nocturnal seizure surveillance devices have not been recommended, installed, or monitored because SUDEP risk communication platforms were inaccessible. Contraindication alert monitoring — preventing sodium channel blocker administration through accessible real-time prescribing decision support — requires continuous platform availability for the alert systems that make non-specialist providers safe for Dravet patients.
Missed contraindication alerts that allow sodium channel blocker prescribing in emergency settings create seizure escalation events that are entirely preventable through accessible digital documentation. Missed fenfluramine cardiac surveillance that delays echocardiography beyond REMS-specified intervals constitutes regulatory non-compliance and valvulopathy detection failure. Missed rescue medication training documentation that leaves school nurses without verified competency creates prolonged seizure risk during school-day events. Platforms that accurately capture contraindication status, cardiac surveillance compliance, rescue protocol training, thermosensitivity logs, and SUDEP risk communication enable multidisciplinary teams to coordinate the medication safety, cardiac monitoring, emergency response, thermosensitivity management, and SUDEP risk mitigation that Dravet syndrome requires across a disease where the pharmacological complexity, thermosensitivity, rescue medication dependency, and SUDEP risk converge in a patient population of young children whose safety depends on continuous digital platform surveillance.
External monitoring from Vigilmon provides the documented, independent availability record that Dravet syndrome program directors can present to hospital administration, neurology program leadership, REMS program auditors, and institutional risk management as evidence that the program's digital infrastructure supports the continuous contraindication safety monitoring, cardiac surveillance compliance, thermosensitivity management, and SUDEP risk mitigation that Dravet syndrome management requires.
Vigilmon Setup for Dravet Syndrome Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Sodium channel blocker contraindication alert platform | 1 min | PagerDuty (immediate, 24/7) | | Fenfluramine REMS cardiac surveillance platform | 1 min | PagerDuty (immediate, 24/7) | | Thermosensitivity and fever monitoring platform | 1 min | PagerDuty (immediate, 24/7) | | Seizure diary and rescue medication protocol platform | 1 min | PagerDuty (immediate, 24/7) | | Precision therapy management platform | 1 min | PagerDuty (immediate, 24/7) | | Cannabidiol hepatotoxicity surveillance platform | 1 min | PagerDuty (immediate, 24/7) | | Neurodevelopmental surveillance platform | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | SUDEP risk monitoring and mitigation platform | 2 min | PagerDuty + Slack (immediate) | | Genetic counseling and SCN1A registry platform | 2 min | PagerDuty + Slack (immediate) | | Multidisciplinary clinic coordination platform | 2 min | PagerDuty + Slack (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) + PagerDuty for contraindication alert failures | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the sodium channel blocker contraindication alert platform at a 1-minute interval with 24/7 PagerDuty alerting as the highest patient safety priority
- Add fenfluramine REMS cardiac surveillance, thermosensitivity monitoring, and seizure diary platforms at a 1-minute interval with immediate 24/7 escalation
- Add precision therapy management and cannabidiol hepatotoxicity surveillance at a 1-minute interval with immediate alerting
- Add neurodevelopmental surveillance and SUDEP risk monitoring at appropriate intervals with immediate alerting
- Add genetic counseling, clinic coordination, and telemedicine platforms with immediate alerting
- Add authentication and EHR synchronization — configure EHR synchronization with elevated alert priority for failures affecting contraindication accessibility in emergency settings
- Enable SSL monitoring across all patient-facing, family-facing, REMS compliance, and thermosensitivity monitoring domains
- Publish the automatic status page URL in family emergency kits, school nurse stations, on-call epileptology systems, and emergency department protocol cards
Conclusion
Dravet syndrome care tech platforms hold the clinical monitoring infrastructure that makes Dravet syndrome management possible across its pharmacologically complex, thermosensitive, treatment-resistant, and SUDEP-risk-elevated clinical landscape — sodium channel blocker contraindication alert platforms providing the prescribing safety infrastructure that protects Dravet patients from the paradoxical seizure worsening that contraindicated antiseizure medications reliably produce through Nav1.1 inhibition that further suppresses the inhibitory interneuron activity that SCN1A haploinsufficiency has already compromised, tracking contraindication status across emergency departments, inpatient units, ambulatory providers, and on-call prescribers who may encounter Dravet patients without immediate specialist documentation and who depend on accessible digital contraindication alerts to prescribe safely in a syndrome where standard antiseizure medications are pharmacologically contraindicated, fenfluramine REMS cardiac surveillance platforms providing the echocardiographic scheduling, result integration, and REMS compliance documentation that fenfluramine therapy requires under its restricted distribution program — with surveillance gaps creating valvulopathy detection failures that the REMS program specifically exists to prevent, thermosensitivity monitoring platforms providing the fever detection, ambient temperature surveillance, rescue medication readiness verification, and emergency protocol activation coordination that continuous thermosensitivity management requires across every environment the Dravet child occupies — recognizing that a missed fever during unmonitored sleep or an undetected ambient temperature threshold during summer outdoor activity represents a seizure risk exposure that timely monitoring prevents, seizure diary and rescue medication coordination platforms providing the seizure frequency documentation, rescue administration timestamp logging, training record management, and emergency protocol distribution that constitute the continuous safety monitoring infrastructure for a syndrome characterized by extreme seizure duration propensity and SUDEP risk that exceeds virtually all other pediatric epilepsy syndromes, precision therapy management platforms integrating fenfluramine, cannabidiol, stiripentol, valproate, and clobazam dosing optimization across the multi-agent pharmacological regimens that most Dravet patients require — with drug interaction surveillance, hepatotoxicity monitoring, and cardiac surveillance compliance ensuring that the approved Dravet-specific therapies are delivered safely, and neurodevelopmental, SUDEP risk, genetic counseling, and multidisciplinary coordination platforms providing the developmental trajectory monitoring, mortality risk management, molecular genetic documentation, and specialist coordination that complete the clinical picture of a syndrome where the convergence of pharmacological complexity, thermosensitivity, treatment resistance, neurodevelopmental regression, and SUDEP risk requires continuous digital platform surveillance to manage safely across every encounter in every care setting. Their availability is a prerequisite for safe disease management and the contraindication protection, cardiac monitoring, thermosensitivity surveillance, rescue protocol coordination, and neurodevelopmental tracking that patients with Dravet syndrome deserve across a disease where platform downtime creates a prescribing safety exposure, a cardiac surveillance gap, a thermosensitivity monitoring failure, and a rescue protocol vulnerability simultaneously — and where every missed contraindication alert, every overdue fenfluramine echocardiogram, every unmonitored fever, every delayed rescue medication, and every nocturnal seizure without detection represents preventable harm in a syndrome where the digital platforms are the primary safety infrastructure for a population managing one of the most dangerous epilepsies in pediatric neurology.
External monitoring from Vigilmon provides the independent, outside-in availability view that Dravet syndrome program directors and health system IT teams need to catch failures before they affect contraindication safety, cardiac surveillance, or thermosensitivity monitoring — with the documented incident record that neurology program leadership, REMS program auditors, institutional risk management, and accreditation bodies accept as evidence of operational maturity in a program managing Dravet syndrome, where platform uptime is directly equivalent to prescribing safety, cardiac monitoring compliance, thermosensitivity management, rescue protocol readiness, and the quality of care that patients with Dravet syndrome deserve when they are most dependent on the pharmacological precision, thermosensitivity management, and rescue protocol coordination that continuous digital platform availability makes possible.
Start monitoring your Dravet Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #DravetSyndrome #SCN1A #Nav1.1 #epilepticEncephalopathy #febrileSeizures #SUDEP #fenfluramine #REMS #cannabidiol #Epidiolex #stiripentol #thermosensitivity #sodiumChannelBlocker #contraindication #seizureRescue #midazolam #pediatricEpilepsy #rareDisease #neurology #healthtech #uptime #clinicaldocumentation #sre